

## Consensus or Controversy? Clinical Investigator Perspectives on the Current and Future Management of Chronic Lymphocytic Leukemia

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- The Phase III ECOG-E1912 and Alliance A041202 trials both compared ibrutinib/rituximab to either fludarabine/cyclophosphamide/rituximab (FCR) or bendamustine/rituximab (BR) for previously untreated chronic lymphocytic leukemia (CLL). Which of the following statements best describes the study design or outcomes of both studies?**

  - Both studies enrolled patients aged 65 or older with del(17p) CLL
  - Data from both studies demonstrate an advantage in progression-free survival (PFS) with the ibrutinib/rituximab combination
  - Data from both studies demonstrate similar efficacy in terms of PFS with and without ibrutinib
- What are the most common side effects associated with ibrutinib-based combination therapies in the management of CLL?**

  - Neutropenia and thrombocytopenia
  - Infections and pneumonia
  - Atrial fibrillation and hypertension
- Which of the following combinations demonstrated a significant PFS advantage in comparison to chlorambucil/obinutuzumab in the Phase III iLLUMINATE study for patients with previously untreated CLL?**

  - Ibrutinib/obinutuzumab
  - Chlorambucil/rituximab
  - Ibrutinib/FCR
- Which mechanism of action is common to the promising investigational agents acalabrutinib and zanabrutinib in the management of CLL?**

  - Selective PI3 kinase delta inhibition
  - Selective Bruton tyrosine kinase inhibition
  - Immune checkpoint inhibition
- Which outcome was reported from the Phase III DUO trial comparing duvelisib to ofatumumab for relapsed/refractory (R/R) CLL or small lymphocytic lymphoma?**

  - Duvelisib significantly improved PFS
  - Duvelisib and ofatumumab yielded similar PFS results
  - Ofatumumab significantly improved PFS
- Which of the following outcomes was reported from the Phase III MURANO trial of venetoclax/rituximab versus BR for R/R CLL?**

  - Venetoclax/rituximab and BR yielded equivalent PFS results
  - Venetoclax/rituximab and BR yielded equivalent overall survival results
  - PFS was longer for patients with undetectable minimal residual disease (MRD)
- Which of the following venetoclax administration strategies is best to mitigate tumor lysis syndrome for patients with CLL, regardless of the tumor burden?**

  - Monotherapy using a 5-week ramp-up with hydration and close monitoring
  - Monotherapy using a 3-week ramp-up with hydration and close monitoring
  - Monotherapy using a 2-week ramp-up with hydration and close monitoring

**Consensus or Controversy? Clinical Investigator Perspectives on the Current and Future Management of Chronic Lymphocytic Leukemia****THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.**

- 8. An ongoing Phase II trial evaluating venetoclax in combination with ibrutinib for previously untreated or R/R CLL has reported which of the following observations for the cohort of patients with previously untreated, high-risk CLL?**
- Responses appear to be dependent on IGHV and TP53 mutation status
  - The rate of complete remission and the rate of undetectable MRD continue to increase as patients remain on therapy**
  - Responses appear to be dependent on del(17p) status
- 9. At the ASH 2018 meeting, Woyach and colleagues presented results from an ongoing Phase II study of which venetoclax-based triplet regimen for patients with treatment-naïve (n = 25) and R/R (n = 25) CLL?**
- Obinutuzumab/acalabrutinib/venetoclax
  - Obinutuzumab/ibrutinib/venetoclax**
  - Rituximab/zanubrutinib/venetoclax
  - Obinutuzumab/chlorambucil/venetoclax
- 10. Which of the following results was reported from the Phase III ASCEND trial evaluating acalabrutinib monotherapy versus investigator's choice of idelalisib/rituximab or BR for R/R CLL?**
- The incidence of hypertension was significantly higher in the acalabrutinib arm than on the idelalisib/rituximab arm
  - The incidence of bleeding events was similar on all 3 arms
  - PFS was superior on the acalabrutinib arm compared to the other 2 arms**